Erik Adolf von Willebrand

Acquired von Willebrand Disease (AvWD) Treatment Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022
Health, Pharmaceutical, Extracorporeal membrane oxygenation, Injection, Diagnosis, Coagulopathy, Awareness, COVID-19, Population, Von Willebrand disease, Novo Nordisk, Bleeding, Research, Cancer, CAGR, Erik Adolf von Willebrand, Ageing, Patient, Blood, ECMO, Genentech, Von Willebrand factor, Growth, World government, Time-invariant system, World Federation of Hemophilia, Haemophilia, Prevalence, Health insurance, Medical device, Pharmaceutical industry

The "Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2022 to 2030.
  • The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease.
  • The demand for the AvWD treatment market has increased as governments across the globe have become increasingly aware of the von Willebrand syndrome and its associated treatment.

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Retrieved on: 
Monday, August 10, 2020
Entertainment, Health, Celebrity, Genetics, Managed care, General Health, Pharmaceutical, Blood, Clinical medicine, Medical specialties, Von Willebrand disease, Haemophilia, Erik Adolf von Willebrand, Coagulopathy, Bleeding, Willebrand, von Willebrand disease (VWD), National Hemophilia Foundation, Takeda Hematology, Takeda Pharmaceutical Company

Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.

Key Points: 
  • Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.
  • "Taking an active role in the bleeding disorder community isn't a choice for me; it's a responsibility," said Borstein.
  • "Von Willebrand disease affects millions of Americans but is often overlooked, even by some healthcare professionals.
  • Takeda is proud to partner with NHF to help raise awareness around VWD.

Versiti Blood Research Institute awarded $13M research grant

Retrieved on: 
Thursday, June 20, 2019
Blood, Medical specialties, Health, Von Willebrand disease, Hematology, Transfusion medicine, National Institutes of Health, Erik Adolf von Willebrand, Bleeding, Von Willebrand factor

MILWAUKEE, June 20, 2019 /PRNewswire/ -- Versiti Blood Research Institute, a national leader in blood health innovation, has been awarded a 5-year, $13.2 million grant from the National Institutes of Health (NIH) to continue its research into von Willebrand disease (VWD), both the most common and undiagnosed bleeding disorder found in patients worldwide.

Key Points: 
  • MILWAUKEE, June 20, 2019 /PRNewswire/ -- Versiti Blood Research Institute, a national leader in blood health innovation, has been awarded a 5-year, $13.2 million grant from the National Institutes of Health (NIH) to continue its research into von Willebrand disease (VWD), both the most common and undiagnosed bleeding disorder found in patients worldwide.
  • Versiti Blood Research Institute has contributed invaluable research through the program for more than a decade.
  • Over the years,the NIH has recognized Versiti Blood Research Institute with more funding than any other blood center in the country.
  • Versiti Blood Center of Wisconsin is a not-for-profit organization headquartered in Milwaukee that specializes in blood services, esoteric diagnostic testing, organ, tissue and stem cell donation, medical services and leading-edge research.